.Attributes Medicine, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Standpoint asks for inclusion of individuals along with MASLD and also size of liver outcomes in cardio-- renal-- metabolic trials, when data propose mechanistically plausible benefits as well as medical safety-- and also outlines points to consider for trial style and regulatory commendation.